Weighing in on the off-label use of actiq™ for noncancer-related pain: A recipe for success or a recipe for disaster?

Pain Medicine

Volumn 8, Issue 2, 2007, Pages 130-133

  Passik, Steven D ^a   Kirsh, Kenneth L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

ActiqTM; Off Label; Opioids; Pain

Indexed keywords

FENTANYL CITRATE; FENTORA; OPIATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL PRACTICE; DRUG ABUSE; DRUG DEPENDENCE; DRUG INDICATION; DRUG INDUSTRY; DRUG USE; HEALTH PRACTITIONER; HUMAN; MIGRAINE; OFF LABEL DRUG USE; PAIN; PATIENT ATTITUDE; PATIENT CARE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PREGNANCY; PRESCRIPTION;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MIGRAINE DISORDERS; PAIN; PREGNANCY; RISK MANAGEMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 33846982239     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00295.x     Document Type: Article

References (15)

1. Actiq [package insert]. Frazer, PA: Cephalon; October 6, 2006. Item number 1598, version number 03. Available at: http://www.actiq.com/pdf/ package_insert.pdf (accessed June 11, 2006).
2. Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML. Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Deliv 2006; 13 (4): 269-76.
3. Fentora [package insert]. Frazer, PA: Cephalon, Inc; 2006. Available at: http://www.fentora.com/hcp/pi.pdf (accessed June 11, 2006).
4. Webster LR. Fentanyl buccal tablets. Expert Opin Investig Drugs 2006; 15 (11): 1469-73.
5. Davies AN. Cancer-related breakthrough pain. Br J Hosp Med (Lond) 2006; 67 (8): 414-6.
6. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006; 22 (9): 805-11.
7. Hojsted J, Nielsen PR, Eriksen J, Hansen OB, Sjogren P. Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: A preliminary study. Acta Anaesthesiol Scand 2006; 50 (10): 1290-6. Epub September 26, 2006.
8. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006; 7 (8): 583-91.
9. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6 (10): 662-72.
10. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28 (2): 176-88.
11. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005; 6 (2): 107-12.
12. Gourlay D, Heit H. Universal precautions: A matter of mutual trust and responsibility. Pain Med 2006; 7 (2): 210-1; author reply 212.
13. Carreyrou J. Narcotic 'lollipop' is big seller despite FDA curbs. The Wall Street Journal, November 3, 2006.
14. Heit HA. Addiction, physical dependence, and tolerance: Precise definitions to help clinicians evaluate and treat chronic pain patients. J Pain Palliat Care Pharmacother 2003; 17 (1): 15-29.
15. Savage SR, Joranson DE, Covington EC, et al. Definitions related to the medical use of opioids: Evolution towards universal agreement. J Pain Symptom Manage 2003; 26 (1): 655-67.